

Lupin launches Tavaborole topical solution in US market

13 July 2021 | News

The product will be manufactured at Lupin's facility in Pithampur



Lupin announced the US launch of Tavaborole Topical Solution, 5 per cent having received approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin's facility in Pithampur.

Tavaborole Topical Solution, 5 per cent, is the generic equivalent of Kerydin Topical Solution, 5 per cent, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*. Tavaborole Topical Solution (RLD: Kerydin), 5 per cent has an estimated annual sales of \$53 million in the US.